Search results for "Heart Disease"

showing 10 items of 489 documents

Haemorheological components in the pre-geriatric and geriatric age range in a randomly selected Western Sicily population sample (Casteldaccia study)

1993

{Received 24.8.1992; accepted 7.12.1992} On a randomly selected western Sicily population sample (Casteldac­ cia Study: 600 subjects; 300 males and 300 females) of an age range from 40 to 79 years, were determined: Haematocrit (Htc) , blood vi­ scosity, plasma viscosity, filterability of whole blood and fibrinogen. Par­ ticipation was 97%, being 582 subjects (M = 287, F = 295). All the parameters measured showed a progressive increase with age and si­ gnificant differences were found between male and female subjects: Htc and blood viscosity were higher in male subjects (p < 0.01), while plasma viscosity, whole blood filterability and fibrinogen were higher in female subjects (p < 0.05). In …

medicine.medical_specialtyPopulation samplePhysiologybusiness.industryBlood viscosityHematologyFibrinogenGastroenterologyCoronary heart diseaseSurgeryPhysiology (medical)Internal medicinemedicineRisk factorCardiology and Cardiovascular MedicinebusinessPlasma viscosityWhole bloodmedicine.drugClinical Hemorheology and Microcirculation
researchProduct

Obstructive sleep apnea and Alzheimer’s disease-related cerebrospinal fluid biomarkers in mild cognitive impairment

2020

Abstract Previous studies have demonstrated that sleep-breathing disorders, and especially obstructive sleep apnea (OSA), can be observed in patients with a higher risk of progression to Alzheimer’s disease (AD). Recent evidence indicates that cerebrospinal fluid (CSF) AD-biomarkers are associated with OSA. In this study, we investigated these associations in a sample of patients with mild cognitive impairment (MCI), a condition that is considered the first clinical phase of AD, when patients showed biomarkers consistent with AD pathology. A total of 57 patients (mean age = 66.19; SD = 7.13) with MCI were included in the study. An overnight polysomnography recording was used to assess objec…

medicine.medical_specialtyHeart diseaseRapid eye movement sleeptau ProteinsPolysomnography03 medical and health sciences0302 clinical medicineAlzheimer DiseasePhysiology (medical)Internal medicinemedicineHumansCognitive DysfunctionAgedSleep Apnea ObstructiveAmyloid beta-Peptidesmedicine.diagnostic_testbusiness.industryApneamedicine.diseaseSleep in non-human animalsPeptide FragmentsObstructive sleep apnea030228 respiratory systemCardiologyNeurology (clinical)medicine.symptombusinessHypopneaBody mass indexBiomarkers030217 neurology & neurosurgerySleep
researchProduct

A proposal to redefine familial combined hyperlipidaemia -- third workshop on FCHL held in Barcelona from 3 to 5 May 2001, during the scientific sess…

2002

Item does not contain fulltext

Pathologymedicine.medical_specialtyLipoproteins and atheroscleroseApolipoprotein Bbiologybusiness.industryClinical BiochemistryGeneral MedicineApolipoproteins bLipoproteïnen en atherosclerose030204 cardiovascular system & hematologyBiochemistryCoronary heart disease03 medical and health sciences0302 clinical medicineClinical investigationInternal medicinebiology.proteinMedicine030212 general & internal medicineFamilial combined hyperlipidaemiabusiness
researchProduct

Cardio‐Renal Biomarker Soluble Urokinase‐Type Plasminogen Activator Receptor Is Associated With Cardiovascular Death and Myocardial Infarction in Pat…

2020

Background Risk stratification among patients with coronary artery disease ( CAD ) is of considerable interest due to the potential to guide secondary preventive therapies. Thus, we evaluated the predictive value of soluble urokinase‐type plasminogen activator receptor (su PAR ) levels for cardiovascular mortality and nonfatal myocardial infarction in patients with CAD . Methods and Results Plasma levels of su PAR were measured in a cohort of 1703 patients with documented CAD as evidenced by coronary angiography—including 626 patients with acute coronary syndrome and 1077 patients with stable angina pectoris. Cardiovascular death and/or nonfatal myocardial infarction were defined as main o…

Malemedicine.medical_specialtyTime FactorsEpidemiologyMyocardial InfarctionRenal functionCoronary Artery Disease030204 cardiovascular system & hematologyKidneyRisk AssessmentReceptors Urokinase Plasminogen Activatorsoluble urokinase‐type plasminogen activator receptorTroponin CCoronary artery disease03 medical and health sciences0302 clinical medicinePredictive Value of TestsRisk FactorsGermanyInternal medicineSecondary PreventionmedicineHumanscardiovascular diseasesMyocardial infarctionReceptorAgedOriginal Research030304 developmental biologyUrokinase0303 health sciencesbusiness.industryMiddle AgedPrognosismedicine.diseaseTroponinC-Reactive ProteinHeart Disease Risk FactorsCardiologybiomarkerBiomarker (medicine)FemaleKidney DiseasesCardiology and Cardiovascular MedicinebusinessPlasminogen activatorBiomarkersGlomerular Filtration Ratemedicine.drugJournal of the American Heart Association
researchProduct

Protection of Azidothymidine-Induced Cardiopathology in Mice by Mildronate, a Mitochondria-Targeted Drug

2006

Azidothymidine, a nucleoside-analogue reverse transcriptase inhibitor (NRTI), is a commonly used antiretroviral drug in AIDS treatment, however its use is limited by severe toxic side effects due to its influence on mitochondria that result in myopathy, particularly affecting the cardiac muscle. We suggest that effective protection of azidothymidine- induced cardiopathology can be expected from drugs that are capable of targeting mitochondria. Therefore the present study in mice was carried out with mildronate, a cardioprotective drug of the aza-butyrobetaine class, which previously has been shown to act as a highly potent protector of mitochondrial processes. In our study, saline (control)…

DrugHeart Diseasesmedia_common.quotation_subjectInflammationMitochondrionPharmacologyToxicologymedicine.disease_causeMiceZidovudinemedicineAnimalsmedia_commonPharmacologyMice Inbred ICRbiologyReverse-transcriptase inhibitorCardiovascular AgentsGeneral MedicineVirologyMitochondriaDisease Models AnimalEnzyme inhibitorbiology.proteinmedicine.symptomZidovudineNucleosideOxidative stressMethylhydrazinesmedicine.drugBasic &lt;html_ent glyph="@amp;" ascii="&amp;amp;"/&gt; Clinical Pharmacology &lt;html_ent glyph="@amp;" ascii="&amp;amp;"/&gt; Toxicology
researchProduct

Cardio-oncology in multiple myeloma: is it time for a specific focus?

2017

It has been known for some time that some oncologic drugs can cause heart damage. The term ‘cardiotoxicity’ just refers to the presence of a cardiac event during therapy or at least related to ther...

Cardiovascular eventCancer Researchmedicine.medical_specialtyHeart DiseasesInterdisciplinary ResearchAntineoplastic Agents030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinemedicineHumansCardio oncologyIntensive care medicineMultiple myelomaFocus (computing)Cardiotoxicitybusiness.industryDisease Managementfood and beveragesHematologymedicine.diseaseCardiotoxicityhumanitiesCardio-oncologyOncologyMultiple MyelomabusinessHeart damage030215 immunology
researchProduct

Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey.

2007

Aims Anderson–Fabry disease (AFD) is an uncommon X-linked disorder caused by deficient activity of the lysosomal enzyme α-galactosidase A. The Fabry Outcome Survey is a European database designed to monitor the long-term efficacy and safety of enzyme replacement therapy (ERT) with agalsidase alfa. The aim of this study was to determine the prevalence and characteristics of cardiac disease in AFD patients. Methods and results Clinical and laboratory data were available in 714 patients from 11 countries (mean age 35 ± 17 years, 369 women, 336 treated). The prevalence of angina was 23 vs. 22%; palpitations and arrhythmias 27 vs. 26%; exertional dyspnoea 23 vs. 23%; and syncope 2 vs. 4%, in wom…

AdultMalemedicine.medical_specialtyHeart diseaseHeart DiseasesCardiomyopathyLeft ventricular hypertrophySyncopeAnginaRisk FactorsInternal medicinemedicinePalpitationsPrevalenceHumansVascular diseasebusiness.industryEnzyme replacement therapyMiddle Agedmedicine.diseaseFabry diseaseRecombinant ProteinsSurgeryEuropeIsoenzymesDyspneaTreatment OutcomeEchocardiographyalpha-GalactosidaseFabry DiseaseFemaleHypertrophy Left Ventricularmedicine.symptomCardiology and Cardiovascular MedicinebusinessGlomerular Filtration RateEuropean heart journal
researchProduct

Mediterranean diet and longevity: an example of nutraceuticals?

2013

The Mediterranean diet (Mediet) is an eating pattern characterizing a lifestyle and culture that has been reported to contribute to better health and quality of life. The Mediet reflects food patterns typical of Mediterranean regions, where olive oil plays an essential role in the food pyramid. Olive oil is located in the middle and it is considered the principal source of dietary fat because of its high nutritional quality (particularly extra virgin olive oil). Several studies have shown the effect of the Mediet on healthy status by lowering the rates of coronary heart disease, certain cancers, and some other age-related chronic diseases. Although the scientific literature regarding diet a…

Mediterranean dietmedia_common.quotation_subjectLongevityNutritional qualityDiet MediterraneanNutraceuticalEnvironmental healthMedicineAnimalsHumansPlant OilsFood scienceDiet ageing LongevityLife StyleOlive Oilmedia_commonPharmacologySettore MED/04 - Patologia Generalebusiness.industryFood pyramidLongevityFeeding BehaviorFood PatternsDietary FatsCoronary heart diseaseDietary SupplementsCardiology and Cardiovascular MedicinebusinessOlive oilCurrent vascular pharmacology
researchProduct

Non-immune hydrops fetalis: Two case reports

2021

BACKGROUND Fetal hydrops is a serious condition difficult to manage, often with a poor prognosis, and it is characterized by the collection of fluid in the extravascular compartments. Before 1968, the most frequent cause was the maternal-fetal Rh incompatibility. Today, 90% of the cases are non-immune hydrops fetalis. Multiple fetal anatomic and functional disorders can cause non-immune hydrops fetalis and the pathogenesis is incompletely understood. Etiology varies from viral infections to heart disease, chromosomal abnormalities, hematological and autoimmune causes. CASE SUMMARY A 38-year-old pregnant woman has neck lymphoadenomegaly, fever, cough, tonsillar plaques at 14 wk of amenorrhea…

Fetusmedicine.medical_specialtyAmniotic fluidHeart diseaseObstetricsbusiness.industryAnemiaFetal transfusionFetal anemiaGeneral Medicinemedicine.diseaseHydrops fetalisPreterm cesarean sectionBlood chemistryInfectious disease (medical specialty)Hydrops fetalisCase reportmedicineEtiologybusinessCordocentesisWorld Journal of Clinical Cases
researchProduct

Dystrophin-deficiency increases the susceptibility to doxorubicin-induced cardiotoxicity

2007

Background and aim: The clinical use of doxorubicin (DOX) and other anthracyclines is limited by a dosage-dependent cardiotoxicity, which can lead to cardiomyopathy. The role of the individual genetic makeup in this disorder is poorly understood. Alterations in genes encoding cardiac cytoskeleton or sarcolemma proteins may increase the susceptibility to doxorubicin-related cardiotoxicity. Methods: Female dystrophin-deficient mice (MDX) and age-matched wild-type mice underwent chronic treatment with doxorubicin. Cardiac function and tissue damage were assessed by echocardiography and histopathology, respectively. Gene expression changes were investigated using microarrays. Results: DOX treat…

Cardiac function curveProgrammed cell deathPathologymedicine.medical_specialtyHeart DiseasesCytoskeleton organizationCardiomyopathyGene Expression030204 cardiovascular system & hematologyDystrophinMice03 medical and health sciences0302 clinical medicineRisk FactorsmedicineAnimalsDoxorubicinUltrasonography030304 developmental biology0303 health sciencesCardiotoxicityAntibiotics AntineoplasticSarcolemmabiologybusiness.industryGenetic VariationMicroarray Analysismedicine.disease3. Good healthDoxorubicinDisease Progressionbiology.proteinCancer researchFemaleDisease SusceptibilityCardiology and Cardiovascular MedicineDystrophinbusinessmedicine.drugEuropean Journal of Heart Failure
researchProduct